Reducing cost of biomanufacturing brazzein in high cell density continuous perfusion bioreactors
Brazzein is a natural sweet protein, originally isolated from a west African berry and closest in taste to sugar among all the natural and artificial sweeteners tested. It is thermo-stable upto 98 deg C and stable over a wide range (2 - 8) of pH.
Sudhin has developed a more efficient continuous biomanufacturing process for brazzein (and other proteins) which reduces the cost of manufacturing. Using our patented BioSettler device as cell retention device to recycle live and productive cells back to the bioreactor, we have achieved very high cell density and productivity in our small lab-scale bioreactors compared to the most commonly used traditional batch or fed-batch fermentation processes. Several global companies have bought our purified brazzein samples (>98% pure) and consider them as a reference standard for brazzein. We are now ready to scale up our more efficient continuous brazzein manufacturing process to pilot and commercial scale.
About Sudhin Biopharma Co
Sudhin Biopharma Co. is a biotechnology company that develops advanced manufacturing technologies for the biopharmaceutical and cell therapy industries. Their core technology, the BioSettler, is a patented device designed for the efficient, continuous separation and retention of cells in bioprocessing applications. Utilizing inclined or conical settling surfaces, these compact devices enable selective cell retention in perfusion bioreactors, which helps maintain high cell densities and viability. The company offers these settlers in various sizes, ranging from laboratory-scale modules to larger, customizable units, including single-use disposable plastic versions, to facilitate tasks such as cell culture clarification, harvesting, washing, and the concentration of therapeutic biologicals like antibodies, viral vectors, and cell therapy products.
These solutions are designed to address the challenges of traditional biological manufacturing by improving process efficiency and productivity. By providing modular devices that can be integrated into existing bioreactor setups, Sudhin Biopharma assists manufacturers in various sectors, including the production of therapeutic biologics, stem cells, organoids, and viral vaccines. The technology has been demonstrated for applications in both mammalian and microbial cell culture, helping to reduce processing times and improve the yield of secreted products. Through collaborations and grant-funded projects, such as those with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the company continues to refine and scale its settling technology to support commercial-scale manufacturing and emerging clinical requirements.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.